Status: Not yet recruiting
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to \<18 years with primary immunoglobulin A nephropathy (IgAN).
Participants needed: 28
Trial details
Phase: Phase 3Age: 2-18Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Jun 23, 2026Locations: 2
Eligibility criteria
Signed informed consent by parent(s)/legal guardian(s) for the pediatric patient... [+7]
Participation in any other investigational drug trial or use of other investigat... [+37]